SKShogo Kobayashi

Shogo Kobayashi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shogo Kobayashi has a total of 603 co-authors. Here are the top co-authors by number of shared publications:

  • Yuichiro Doki

    Department of Gastroenterological Surgery Graduate School of Medicine the University of Osaka Suita City Osaka Japan

    162 shared publications
  • Yoshito Tomimaru

    Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan

    105 shared publications
  • Hidetoshi Eguchi

    Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan

    97 shared publications
  • Hidetoshi Eguchi

    Department of Gastroenterological Surgery, Graduate School of Medicine The University of Osaka Suita Japan

    95 shared publications
  • Yoshifumi Iwagami

    Department of Gastroenterological Surgery Graduate School of Medicine the University of Osaka Suita City Osaka Japan

    83 shared publications
  • Takehiro Noda

    Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan

    80 shared publications

Latest Publications

  • Open Access

    Relationship Between Radiographic and Pathological Portal Vein‐Superior Mesenteric Vein Involvement in Neoadjuvant Treatment for Pancreatic Cancer: A Comparative Study of Neoadjuvant Chemotherapy and Chemoradiotherapy

    by Naoko Sekiguchi, Hidenori Takahashi, Hirofumi Akita, Kazuki Sasaki, Shinichiro Hasegawa, Yoshifumi Iwagami, Daisaku Yamada, Yoshito Tomimaru, Tadafumi Asaoka, Takehiro Noda, et al.

    Background: The relationship between the radiographic portal vein‐superior mesenteric vein (PV‐SMV) involvement and pathological PV‐SMV (pPV) invasion has been established in upfront surgery cases of pancreatic cancer (PC); however, evidence remains limited for patients receiving neoadjuvant therapy (NAT). This study aimed to evaluate the association of radiographic findings with pPV invasion in patients treated with NAT, and to examine whether this association differs between patients treated with neoadjuvant chemotherapy (NAC) and neoadjuvant chemoradiotherapy (NACRT). Methods: We retrospectively analyzed patients with PC whose tumors contacted the PV‐SMV on radiographic imaging before or after NAT. The relationship between radiographic findings and pPV invasion was evaluated in subgroups defined by pre‐ and post‐NAT imaging findings. Results: Tumor size, PV‐SMV contact length, and contact angle were significantly reduced in post‐NAT imaging. Radiographic PV‐SMV involvement showed limited association with pPV invasion in the entire cohort. The overall pPV invasion rate was 15% and did not differ between the NAC and NACRT groups (17% vs. 13%, p = 0.790). Among patients with a pre‐NAT tumor size of < 20 mm, the pPV invasion rate was significantly lower in the NACRT group than in the NAC group (29% vs. 0%, p = 0.007). This difference was not observed in patients with a pre‐NAT tumor size ≥ 20 mm (12% vs. 19%, p = 0.438). Across other radiographic classifications, pPV invasion rates remained comparable between treatment groups. Conclusions: The association of radiographic findings with pPV invasion differs between patients treated with NAC and NACRT in patients with small tumors.

  • Can preoperative spirometry be omitted for HBP surgery?

    by Takeshi Kado, Yoshito Tomimaru, Shogo Kobayashi, Kazuki Sasaki, Shinichiro Hasegawa, Daisaku Yamada, Hirofumi Akita, Takehiro Noda, Hidenori Takahashi, Yuichiro Doki, et al.

  • IL-33 released during liver resection facilitates intrahepatic cholangiocarcinoma growth via cytokine secretion in cancer-associated fibroblasts

    by Satoshi Eguchi, Daisaku Yamada, Shogo Kobayashi, Kazuki Sasaki, Yoshifumi Iwagami, Chihiro Yamanaka, Yoshito Tomimaru, Takehiro Noda, Masaki Sakaue, Tadafumi Asaoka, et al.

    Background We previously reported that IL-33 released during hepatectomy contributes to cytokine-facilitated iCCA tumor growth. However, the underlying mechanisms of the tumor microenvironment remain unexplored. In this study, we aimed to elucidate the impact of IL-33 on cancer-associated fibroblasts (CAFs). Methods The abundance of IL-33-positive cells and alpha-SMA-positive fibroblasts (myoCAFs) was evaluated using resected specimens. Next-generation sequencing (NGS) was performed for comprehensive expression analysis. The effects of IL-33 stimulation on CAFs were investigated in vitro and in vivo using human and murine iCCA cell lines, as well as fibroblasts extracted from resected specimens. Results IL-33-positive cells and myoCAFs were significant risk factors for intrahepatic recurrence. NGS analysis revealed significant upregulation of various cytokines in cases with high number of IL-33-positive cells. The conditioned medium obtained from fibroblasts stimulated with IL-33 enhanced the proliferation and migration of iCCA cell lines. Among the cytokines that were increased by IL-33 stimulation in vitro, IL-6 was suspected to be the dominant. In a murine syngraft model, hepatectomy led to an increased subcutaneous tumor volume by releasing IL-33, whereas IL-6 blockade suppressed this growth. Conclusions This study indicated that IL-33 facilitates iCCA growth through fibroblast activation and is associated with intrahepatic recurrence.


  • Open Access

    Neoadjuvant Chemotherapy With Gemcitabine/Cisplatin/S‐1 for Resectable Biliary Tract Cancer With FDG ‐ PET ‐Positive Lymph Node Metastasis ( KHBO1201 ): A Multicenter Phase II Trial

    by Satoshi Ogiso, Etsuro Hatano, Satoru Seo, Masashi Kanai, Shogo Kobayashi, Hiroshi Wada, Hidetoshi Eguchi, Tatsuya Higashi, Hiroaki Nagano, Tatsuya Ioka

    Purpose: To evaluate the safety and efficacy of neoadjuvant gemcitabine, cisplatin, and S‐1 (GCS) chemotherapy for resectable biliary tract cancer (BTC) and FDG‐PET‐positive lymph nodes in a multicenter phase II study (KHBO1201). Methods: Patients with resectable BTC (intrahepatic/extrahepatic bile duct, gallbladder, or ampullary cancers) and FDG‐PET‐positive lymph nodes received GCS chemotherapy: gemcitabine/cisplatin on Day 1 and oral S‐1 for 7 days, repeated every 2 weeks for 3–6 cycles. Surgery was planned 4–8 weeks later if the tumor was deemed resectable. The primary endpoint was the curative resection rate. Secondary endpoints were the completion rate, radiological response, radiological/pathological complete response (CR) of FDG‐PET‐positive lymph nodes, and 1‐year survival (UMIN000009831). Results: Twenty‐five patients were enrolled. Twenty‐three (92%) completed GCS without treatment‐related deaths; grade 3 biliary infection occurred in 8.0%. Curative resection was achieved in 60% with a morbidity rate of 40%. The radiological response rate was 13%, and the radiological and pathological CR rates of FDG‐PET‐positive lymph nodes were 24% and 28%, respectively. The 1‐year survival rate was 75%. Conclusions: Neoadjuvant GCS chemotherapy is safe, feasible, and potentially effective for resectable BTC with FDG‐PET‐positive lymph nodes. A randomized phase III trial (JCOG1920) is underway to compare neoadjuvant GCS chemotherapy with upfront surgery (jRCTs031200388).


  • Open Access

    Post hoc subgroup analysis of neoadjuvant gemcitabine plus S1 vs gemcitabine plus nab paclitaxel in elderly resectable/borderline resectable pancreatic adenocarcinoma

    by Daisaku Yamada, Shogo Kobayashi, Hidenori Takahashi, Yoshifumi Iwagami, Hirofumi Akita, Kei Asukai, Junzo Shimizu, Terumasa Yamada, Masahiro Tanemura, Shigekazu Yokoyama, et al.

    This study aimed to evaluate the safety and feasibility of two neoadjuvant chemotherapy (NAC) regimens, gemcitabine plus nab-paclitaxel (GA) and gemcitabine plus S-1 (GS), for elderly patients (aged 75 years and older) with resectable and borderline resectable pancreatic ductal adenocarcinoma (R/BR-PDAC). A post hoc analysis was conducted using data from a randomized controlled trial on NAC for R/BR-PDAC (CSGO-HBP-015). Patients were divided into two groups: those aged 75 years and older (7/46 in GS and 16/48 in GA) and those under 75 years. Short-term outcomes, including resection rates, adverse events (AEs), postoperative complications, and the administration of adjuvant chemotherapy, were compared between age groups for both regimens. The incidence of AEs in patients aged 75 years and older tended to be higher than those of younger patients in both chemotherapy arms, but the differences were not statistically significant. However, the resection rates, postoperative complication rates, and the administration of adjuvant chemotherapy were not affected by age. Both regimens showed comparable safety profiles in elderly and younger cohorts. The GA and GS regimens can be safely administered as NAC for R/BR-PDAC in elderly patients without adversely affecting postoperative outcomes. These findings suggest that both regimens are feasible NAC options even for patients 75 years and older, supporting the need for further randomized controlled trials to validate these outcomes in the elderly population. Trial registration . UMIN Clinical Trials Registry UMIN000021484. This trial began in April 2016, and first registration (First Posted date) is 01/04/2016.


  • Response to the letter to the editor: “Refining the prognostic utility of CA19-9 in neoadjuvant therapy for pancreatic cancer: Emphasizing serial monitoring and subgroup differentiation”

    by Satoru Miyahara, Hidenori Takahashi, Yoshito Tomimaru, Shogo Kobayashi, Kazuki Sasaki, Daisaku Yamada, Hirofumi Akita, Takehiro Noda, Yuichiro Doki, Hidetoshi Eguchi

  • Open Access

    Tumor Endothelial Cells Induce M2 Macrophage Polarization via IL ‐4, Enhancing Tumor Growth in Hepatocellular Carcinoma

    by Daijiro Matoba, Takehiro Noda, Shogo Kobayashi, Yoshihiro Sakano, Kenichi Matsumoto, Chihiro Yamanaka, Kazuki Sasaki, Shinichiro Hasegawa, Yoshifumi Iwagami, Daisaku Yamada, et al.

    Tumor‐associated macrophages (TAMs) and tumor endothelial cells (TECs) are important components in tumor microenvironments. This study examined the interaction between TECs and TAMs in hepatocellular carcinoma (HCC). The aim of this study is to clarify the mechanism of immune suppression and cancer progression mediated by the M2 polarization of TAMs. TECs were isolated from subcutaneous HCC tumors using murine BNL‐T cells, and normal endothelial cells (NECs) were isolated from murine liver. M0 macrophages were obtained from bone marrow after incubation with M‐CSF. Conditioned medium from TECs (TEC CM) or NECs (NEC CM) was added to M0 macrophages, and the polarization to M2 macrophages was assessed. The percentage of iNOS − CD206 + cells was increased in the TEC CM group than in the NEC CM group. The subcutaneous tumor model with co‐injection of BNL‐T and TECs or NECs was applied, and the ratio of M2 macrophages (CD206 + iNOS − CD45 + CD11b + F4/80 + cells) was elevated in the BNL‐T + TEC group. IL‐4 expression in TECs was upregulated compared to NECs, and the secretion of IL‐4 was increased in the TEC CM compared to the NEC CM. After IL‐4 down‐regulation in TECs, the ratio of iNOS − CD206 + cells decreased. The double immunofluorescent staining of CD31 and CD163 was performed in human HCC tissue. The number of CD31 + endothelial cells correlated positively with CD163 + TAMs. The high CD163/CD31 group showed poor prognosis in overall and disease‐free survival. TECs induce M2 macrophage polarization through IL‐4 secretion, leading to immune suppression and cancer progression.


  • Laparoscopic Liver Resection for Small, Solitary, Peripheral-Type Intrahepatic Cholangiocarcinoma, Based on Preoperative Prediction of Lymph Node Metastasis

    by Hirotoshi Takayama, Shogo Kobayashi, Kunihito Gotoh, Kazuki Sasaki, Yoshifumi Iwagami, Daisaku Yamada, Yoshito Tomimaru, Hirofumi Akita, Tadafumi Asaoka, Takehiro Noda, et al.

    Aim: Laparoscopic liver resection (LLR) for intrahepatic cholangiocarcinoma (ICC) is not as widespread as LLR for hepatocellular carcinoma or liver metastasis, mainly because ICC may require a lymph node dissection (LND). However, small, solitary, peripheral-type ICC rarely have lymph node metastasis (LNM). The aim of the current study is to examine the usefulness of LLR for ICC and determine whether our criteria for applying LLR without LND to small, solitary, peripheral-type ICC was appropriate. Methods: We retrospectively selected 78 patients that underwent liver resections for ICC at Osaka University Hospital between 2003 and 2020. We compared LLR ( n = 13) to open liver resection (OLR, n = 65) for short-term and long-term outcomes. We also analyzed a subgroup ( n = 29) with small, solitary, peripheral-type ICC. Results: The LLR group had less blood loss ( P < .001), shorter postoperative stays ( P < .001), and significantly higher 5-year recurrence-free survival (RFS, 74.0%), compared to the OLR group (29.6%, P = .030). However, the OLR group included a higher proportion of patients with advanced ICC. Among patients with small, solitary, peripheral-type ICC, LLR ( n = 10) was associated with less blood loss ( P = .004) and shorter postoperative stays ( P = .002), compared to OLR ( n = 19). These groups had similar pathological findings, similar 5-year RFS (75.0% versus 56.8%; P = .433), and similar 5-year overall survival (75.0% versus 80.4%; P = .530). No patients that underwent LLR without LND for ICC experienced lymph node recurrence. Conclusions: Among patients with ICC, LLR provided better intraoperative and short-term outcomes than OLR, and comparable oncological outcomes. Furthermore, no patients that underwent LLR without LND for ICC experienced lymph node recurrence. LLR without LND for ICC can be performed safely and feasibly by selecting patients with small, solitary, peripheral-type ICC.


  • ASO Visual Abstract: Efficacy of SOAT1 Inhibitors Against Pancreatic Cancer with TP53 Mutations

    by Ryosuke Maki, Yoshifumi Iwagami, Shogo Kobayashi, Kazuki Sasaki, Daisaku Yamada, Yoshito Tomimaru, Daisuke Sakai, Takehiro Noda, Tadafumi Asaoka, Hidenori Takahashi, et al.

  • ASO Author Reflections: Efficacy of SOAT1 Inhibitors against Pancreatic Cancer with TP53 Mutations

    by Ryosuke Maki, Yoshifumi Iwagami, Shogo Kobayashi, Kazuki Sasaki, Daisaku Yamada, Yoshito Tomimaru, Daisuke Sakai, Takehiro Noda, Tadafumi Asaoka, Hidenori Takahashi, et al.